TAVI: emergency surgery is rare

Original title: Emergent cardiac surgery during transcatheter aortic valve implantation (TAVI): insight from Edwards SAPIENS Aortic Bioprótesis European Outcome (SOURCE) registry Reference: Holger Eggebrecht, et; al. Eurointervention 2013; 9online publish-ahead of print november 2013

Percutaneous aortic valve implantation has grown significantly since its inception, to be a safe procedure. The need for emergency cardiac surgery is rare, its causes and impact still little known. 

2307 patients from SOURCE Registry were analyzed, of whom 27 (1.2 %) required emergency surgery. Most of these were women and more frequent access was trans-apical (16/ 59%), there was no difference in other points with the rest of the population. The most frequent cause was embolization / migration (9/ 33%) followed by aortic dissection and perforation lesions (7/26 %). Other causes were aortic annulus rupture (3/ 11%), severe percutaneous valvular insufficiency (3/11), cardiac tamponade (2/7 %), apical access bleeding (1/4 %),    coronary obstruction (1 / 4%) and failure in the release process (1/ 4%). Immediate mortality    (within 72 hours, VARC -2) occurred in 10 patients (37 %) and after 30 days at 51.9 % compared with 7.6 % in the rest of the population. Mortality after the first month reaches 70 %. Death was associated to the cause that motivates surgery, so 3 patients showed rupture of the aortic annulus died the 2 patients with severe cardiac tamponade, 7 with migration / embolism and 4 who had aortic lesions. The most common cause of death after surgery was low cardiac volume minute / cardiogenic shock, followed by multiple organ failure, bleeding and stroke.

Conclusion

The rate of emergency surgery is low, with a mortality of 52% after 30-day. Acute dramatic complications (ring rupture or aortic injury) have a high mortality. Preventing complications requiring emergency surgeries are important, in that way, less traumatic and more flexible devices reduce the risk of aortic injury and migration; these being the two most common causes. 

Comment

TAVI has proven effective and safe, and the need for surgery is rare (between 0.1 % and 1.2 %), but having a strong negative impact on the short- term. It is essential to have an excellent surgeon and heart team experience, when indicate and perform these interventions. Surely, with the development of new and better valves the need for emergency surgery will decrease. 

Courtesy of Dr Carlos Fava
Interventional cardiologist
Fundación Favaloro – Argentina

Dr. Carlos Fava para SOLACI.ORG

More articles by this author

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...

ACC 2026 | CHAMPION-AF: Left atrial appendage closure versus anticoagulation in atrial fibrillation

Can left atrial appendage closure challenge anticoagulation as the standard of care in atrial fibrillation? Atrial fibrillation (AF) is the most common sustained arrhythmia and...

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...